Johnson & Johnson has been dedicated to developing treatments for inflammatory bowel disease (IBD) for decades, culminating in the recent FDA approval of a promising new medication for moderate to severe ulcerative colitis (UC). IBD, which includes Crohn’s disease and UC, affects up to 10 million people worldwide and remains without a cure.

The company has pioneered numerous advancements in IBD treatment, from the first biologic therapy in the 1990s to the development of innovative immune-modulating drugs. Their latest therapy, a dual-acting monoclonal antibody, has shown significant symptom improvement and intestinal healing in clinical trials.

Ongoing research focuses on groundbreaking approaches such as mucosal immunology and combination therapies using multispecific antibodies to enhance treatment effectiveness. Johnson & Johnson remains committed to raising the standard of care for IBD patients through continuous innovation.
JNJ